


Antiproliferative agent-12

Cat. No.:	HY-150969
Molecular Formula:	C ₄₆ H ₄₀ Cl ₂ N ₆ P ₂ Ru
Molecular Weight:	910.79
Target:	Mitochondrial Metabolism
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Antiproliferative agent-10 (compound 1) is an anti-tumour ruthenium(II)-tris-pyrazolylmethane complex that inhibits the growth of cancer cells by inhibiting mitochondrial calcium uptake ^[1] .								
In Vitro	<p>Antiproliferative agent-10 (compound 1) (1.5-5.8 μM, 72 h) has significantly anti-cancer cell proliferative activity and effectively induces apoptosis in HCT116 cells^[1].</p> <p>Antiproliferative agent-10 (15 μM, 24 h) shows HCT116 cell survival rates of 93% to 97% and ruthenium content of cell was 145.1 ng/10⁶ cells, so that it can accumulate efficiently in the cells and promote their biological activity^[1].</p> <p>Antiproliferative agent-10 (3-10 μM, 5 h) can cause mitochondrial depolarization in a concentration-dependent manner and inhibit mitochondrial calcium uptake^[1].</p> <p>Antiproliferative agent-10 can inhibit the formation and growth of spheroids of HCT116 cells with an IC₅₀ value of 2.5 μM, approximately 18-fold more effective than cisplatin and almost completely disintegrate of the spheroids^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Proliferation Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>MCF-7 (breast), HeLa (cervical), 518A2 (melanoma), HCT116 (colon), RD (rhabdomyosarcoma)</td> </tr> <tr> <td>Concentration:</td> <td>1.5-5.8 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>72 hours</td> </tr> <tr> <td>Result:</td> <td>Inhibited the proliferation of MCF-7, HeLa, 518A2, HCT116 and RD with the IC₅₀ values of 2.4, 4, 2.6, 1.5 and 2.2 μM, respectively.</td> </tr> </table>	Cell Line:	MCF-7 (breast), HeLa (cervical), 518A2 (melanoma), HCT116 (colon), RD (rhabdomyosarcoma)	Concentration:	1.5-5.8 μM	Incubation Time:	72 hours	Result:	Inhibited the proliferation of MCF-7, HeLa, 518A2, HCT116 and RD with the IC ₅₀ values of 2.4, 4, 2.6, 1.5 and 2.2 μM, respectively.
Cell Line:	MCF-7 (breast), HeLa (cervical), 518A2 (melanoma), HCT116 (colon), RD (rhabdomyosarcoma)								
Concentration:	1.5-5.8 μM								
Incubation Time:	72 hours								
Result:	Inhibited the proliferation of MCF-7, HeLa, 518A2, HCT116 and RD with the IC ₅₀ values of 2.4, 4, 2.6, 1.5 and 2.2 μM, respectively.								

REFERENCES

[1]. Jakub Cervinka, et al. Ruthenium(II)-Tris-pyrazolylmethane Complexes Inhibit Cancer Cell Growth by Disrupting Mitochondrial Calcium Homeostasis. J Med Chem. 2022 Aug 1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA